Management of non-small-cell lung cancer: recent developments (Q38131165)

29 August 2017

title

Management of non-small-cell lung cancer: recent developments (English)

1 reference

29 August 2017

1 reference

Jean-Charles Soria

0 references

K.F. Rabe

series ordinal

object named as

Klaus F Rabe

1 reference

29 August 2017

Martin Reck

1 reference

29 August 2017

David F Heigener

series ordinal

1 reference

29 August 2017

Tony Mok

series ordinal

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

382

1 reference

29 August 2017

issue

9893

1 reference

29 August 2017

page(s)

709-719

1 reference

29 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Lung cancer--time to move on from chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Preoperative staging of lung cancer with combined PET-CT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Endoscopic and endobronchial ultrasonography according to the proposed lymph node map definition in the seventh edition of the tumor, node, metastasis classification for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Transbronchial and transoesophageal (ultrasound-guided) needle aspirations for the analysis of mediastinal lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

VATS lobectomy in stage I lung cancer: standard or experimental procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Incidence of local recurrence and second primary tumors in resected stage I lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

ERCC1 and RRM1: ready for prime time?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

What can be done for patients with NSCLC without druggable targets?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Determining the appropriate sleeve lobectomy versus pneumonectomy ratio in central non-small cell lung cancer patients: an audit of an aggressive policy of pneumonectomy avoidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Personalized medicine in lung cancer: what we need to know.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

ALK in lung cancer: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961502-0

7 January 2021

10.1016/S0140-6736(13)61502-0

Identifiers

DOI

1 reference

29 August 2017

1 reference